Celltrion is widening its search for biotech innovation beyond Korea’s borders. On Tuesday, the Korean biopharma manufacturer signed a fresh deal with Seoul Biohub to launch a revamped open innovation program aimed at scouting overseas biotech and medtech startups with tech that could plug directly into its pipeline.

The tie-up marks Celltrion’s first push to globalize its open innovation strategy after supporting six domestic startups last year in immuno-oncology, microbiome research, and small molecule R&D.

This year, the new Global Open Innovation program will shortlist around 10 overseas candidates before selecting two final picks in 2025 for full-scale support. 

The companies will be chosen based on their ability to create synergy with Celltrion’s core research areas—especially in antibody-based therapies, next-gen modalities, drug delivery platforms, and small molecule innovation, the company said.

Winners will receive tailored mentoring from Celltrion’s drug development team, including guidance on global R&D trends, strategic project planning, and pipeline development. Seoul Biohub—a city-run startup incubator managed by Korea Institute of Science and Technology (KIST) and Korea University—will provide the infrastructure for a soft landing in Korea, including lab access, local network support, and exposure to domestic and international VCs through curated demo days.

One of last year’s picks, Enterobiome, has already broken out internationally, landing a spot in Japan’s Kansai Life Science Accelerator Program after Celltrion’s support.

“We’ll keep pushing for joint growth through platform and pipeline partnerships,” a Celltrion spokesperson said, adding the company aims to build a global biotech ecosystem by extending its startup playbook overseas.